Globally, lung cancer is the leading cause of cancer-related mortality among both men and
women, and while mortality associated with the disease has demonstrated relative stability …

Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …

Background The strategy of dual inhibiting epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor (VEGF) pathways has been extensively investigated in …

目的NCCN 指南推荐厄洛替尼作为伴有EGFR 突变的晚期非小细胞肺癌(non-small cell lung
cancer, NSCLC) 一线治疗的标准方案, 但厄洛替尼与贫血发生的相关性无相应的系统评价参考 …

Assessing the quality of and integrating clinical trial reports are necessary to practice
evidence-based medicine. In particular, the numerical data is essential to understanding the …

Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced
non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials - PMC Back …

Background: Whether erlotinib plus tivantinib (ET) can achieve better clinical benefits than
erlotinib plus placebo (EP) among participants with previously treated advanced non-small …

Lung cancer is the most commonly diagnosed cancer as well as the leading cause of cancer
related death worldwide. Till date, surgery is the treatment of first choice for lung cancer. But …

Breast cancer is the most common cancer among Canadian women and 14-20% will
develop lethal metastases within 5 years. A potential novel therapeutic target is Focal …

Clinical trial experimental studies are the gold standard for obtaining evidence related to
interventions for a given disease or chronic condition, and currently results are documented …